Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-Intensity Allogeneic HSCT for High-Risk Hematological Malignancies
NCT01139164Phase 2Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Jun 2010
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of iodine i 131 tositumomab in hematological malignancies, chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and 2 more (3 arms), sponsored by Medical University of South Carolina. Primary endpoint: Treatment-related Mortality Rate at 100 days. Started Jun 2010; status: terminated.
02
Drugs
iodine i 131 tositumomab
03
Conditions
hematological malignancieschronic lymphocytic leukemia (CLL)multiple myeloma (MM)B cell lymphomaprolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on NCT01139164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01139164.